A human natural killer cell enhancing factor C and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating viral infections, inflammation, neoplasia and damage from superoxide radicals. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.

Claims

42 · 2 independent · depth 5

42 granted claims

›1.independentAn isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding amino acids 1-271 o…+23

›2.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (a).d2+6

›4.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (b).d2+1

›8.↳ 1The isolated nucleic acid molecule of claim 1 fused to a heterologous polynucleotide.d2+1

›10.↳ 1The isolated nucleic acid molecule of claim 1, wherein the polynucleotide is DNA.d2

›11.↳ 1The isolated nucleic acid molecule of claim 1, wherein the polynucleotide is double stranded.d2

›12.↳ 1A recombinant vector comprising the nucleic acid molecule of claim 1.d2

›13.↳ 1A recombinant host comprising the nucleic acid molecule of claim 1 operatively associated with a heterologous regulatory sequence.d2+1

›15.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (d).d2

›16.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (e).d2

›17.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (f).d2

›18.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (g).d2

›19.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (h).d2

›20.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (i).d2

›21.↳ 1The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is (j).d2

›22.independentAn isolated nucleic acid molecule consisting of a polynucleotide selected from the group consisting of: (a) a polynucleotide encoding amino acids 1-27…+17

›23.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (a).d2+1

›27.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (c).d2

›29.↳ 22The isolated nucleic acid molecule of claim 22 fused to a heterologous polynucleotide.d2+1

›31.↳ 22The isolated nucleic acid molecule of claim 22, wherein the polynucleotide is DNA.d2

›32.↳ 22The isolated nucleic acid molecule of claim 22, wherein the polynucleotide is double stranded.d2

›33.↳ 22A recombinant vector comprising the nucleic acid molecule of claim 22.d2

›34.↳ 22A recombinant host comprising the nucleic acid molecule of claim 22 operatively associated with a heterologous regulatory sequence.d2+1

›36.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (d).d2

›37.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (e).d2

›38.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (f).d2

›39.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (g).d2

›40.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (h).d2

›41.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (i).d2

›42.↳ 22The isolated nucleic acid molecule of claim 22, wherein said polynucleotide is (j).d2

Classifications

10 codes

USPC · US Patent Classification

435/69.5435/70.1435/471435/320.1435/71.1536/23.5536/23.1435/252.3530/351435/325

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

4.4 y

1,624 days filing → grant

Office actions

on the grant's record

Examiner

Prema Mertz

art unit —

Law firm

Law firm · Log in to unlock

Citations: 10 back · 0 forward

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.